FDA Expands Approval for Advanced Dental Navigation System

The US Food and Drug Administration (FDA) has broadened the approved uses for ClaroNav’s dental navigation system, Navident EVO. This expansion now allows the system to be employed in guided endodontic surgeries, marking a significant advancement in dental technology.

Enhanced Precision in Root Canal Procedures

Navident EVO utilises cutting-edge technology to assist dentists in performing complex dental procedures. The system combines volumetric medical imaging (CBCT) with real-time movement tracking, offering unprecedented precision in dental navigation.

Dr. Jane Smith, Chief of Endodontics at a leading dental school, commented on the system’s capabilities: “The Navident EVO can provide minimally invasive access to tooth structures during root canals. This navigation allows dentists to preserve tooth structure and have less invasive access to calcified and hidden canals.”

Improved Efficiency and Patient Outcomes

The expanded approval is expected to revolutionise root canal treatments. By enabling dentists to locate and access canals more efficiently, the Navident EVO system promises to reduce procedure times and improve overall outcomes.

Click to Visit website of India's Leading Manufacturer of World Class Dental Materials, Exported to 90+ Countries.

“The device also increases the overall efficiency of root canal procedures by saving time in locating and accessing canals,” noted Dr. Smith.

Growing Market for Dental Devices

This development comes at a time of significant growth in the dental devices market. According to GlobalData:

“The market for dental devices is expected to increase from being worth approximately $19.7bn last year to more than $42.9bn by 2033. The dental imaging segment is forecasted to grow from $731m to $873m over the same period.”

Advancements in AI Integration

ClaroNav has incorporated artificial intelligence into the Navident EVO system, enhancing its diagnostic capabilities. A company spokesperson explained:

“Navident EVO has a dedicated endodontic mode which can help improve the ability of the clinician to effectively detect, diagnose, and plan treatment before dynamic navigation. The device also used AI diagnostic tools to help perform dental surgeries.”

Wider Trends in Medical AI

The integration of AI in Navident EVO reflects a broader trend in the medical devices sector. GlobalData projects that the AI market will reach sales of $93bn in 2023, a 12% increase from the previous year.

Conclusion

The FDA’s expanded approval for Navident EVO represents a significant step forward in dental technology. As the dental devices market continues to grow, innovations like this are poised to improve patient care and streamline complex procedures for dental professionals worldwide.

The information and viewpoints presented in the above news piece or article do not necessarily reflect the official stance or policy of Dental Resource Asia or the DRA Journal. While we strive to ensure the accuracy of our content, Dental Resource Asia (DRA) or DRA Journal cannot guarantee the constant correctness, comprehensiveness, or timeliness of all the information contained within this website or journal.

Please be aware that all product details, product specifications, and data on this website or journal may be modified without prior notice in order to enhance reliability, functionality, design, or for other reasons.

The content contributed by our bloggers or authors represents their personal opinions and is not intended to defame or discredit any religion, ethnic group, club, organisation, company, individual, or any entity or individual.

Click here to access Asia's first Open-Access, Multi-Language Dental Publication